Valuation: Evofem Biosciences, Inc.

Market Cap 808K 720K 659K 600K 1.13M 76.4M 1.16M 7.92M 3.17M 40.46M 3.03M 2.97M 128M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.23M 49.21M 45.01M 40.99M 77.27M 5.22B 79.35M 541M 216M 2.76B 207M 203M 8.72B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day-4.54%
1 week-0.81%
Current month+1.67%
1 month-17.57%
3 months-27.38%
6 months+1.67%
Current year-35.79%
1 week 0.01
Extreme 0.00575
0.01
1 month 0.01
Extreme 0.00575
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.01
3 years 0
Extreme 0.0008
0.23
5 years 0
Extreme 0.0008
1,294.87
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 31/12/2017
Director of Finance/CFO 49 12/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 31/12/2017
Director/Board Member 58 31/12/2017
Date Insider Type Main position Quantity % Market Cap. Importance
12/01/24 Sell

Chief Financial Officer

104 0.0010%
21/12/23 Sell

Director

10 0.0001%
13/04/23 Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-4.54%-0.81% - - 808K
Average -4.54%
Weighted average by Cap. -4.54%

Financials

2024 2025
Net sales 19.36M 17.25M 15.78M 14.37M 27.09M 1.83B 27.82M 190M 75.82M 969M 72.68M 71.12M 3.06B 20.18M 17.99M 16.45M 14.98M 28.24M 1.91B 29M 198M 79.03M 1.01B 75.76M 74.13M 3.19B
Net income -8.86M -7.9M -7.22M -6.58M -12.4M -837M -12.73M -86.76M -34.69M -443M -33.26M -32.54M -1.4B 391K 348K 319K 290K 547K 36.95M 562K 3.83M 1.53M 19.57M 1.47M 1.44M 61.75M
Net Debt 45.84M 40.85M 37.36M 34.03M 64.14M 4.33B 65.87M 449M 179M 2.29B 172M 168M 7.24B 54.42M 48.49M 44.35M 40.39M 76.14M 5.14B 78.19M 533M 213M 2.72B 204M 200M 8.59B
Projected Income Statement - Annual - Evofem Biosciences, Inc.
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
05/11/26 US$0.006100 -4.54% 345,535
04/11/26 US$0.006390 +4.75% 101,387
03/11/26 US$0.006100 +1.67% 166,145
02/11/26 US$0.006000 0.00% 80,938
30/10/26 US$0.006000 -2.44% 56,930

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Evofem Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. EVFM Stock